{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:28:10Z","timestamp":1771655290375,"version":"3.50.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002927","name":"Addenbrooke's Charitable Trust, Cambridge University Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004282","name":"Evelyn Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004282","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bpgastro.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.bpg.2014.04.005","type":"journal-article","created":{"date-parts":[[2014,5,4]],"date-time":"2014-05-04T20:46:22Z","timestamp":1399236382000},"page":"437-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Not all monoclonals are created equal \u2013 Lessons from failed drug trials in Crohn's disease"],"prefix":"10.1016","volume":"28","author":[{"given":"Arthur","family":"Kaser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2014.04.005_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobaton","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2014.04.005_bib4","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib5","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0140-6736(93)91375-V","article-title":"Tumour-necrosis-factor antibody treatment in Crohn's disease","volume":"342","author":"Derkx","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2014.04.005_bib8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","article-title":"Inflammatory bowel disease","volume":"28","author":"Kaser","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib9","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10208","article-title":"Intestinal homeostasis and its breakdown in inflammatory bowel disease","volume":"474","author":"Maloy","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bpg.2014.04.005_bib11","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0016-5085(03)00385-8","article-title":"Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics","volume":"124","author":"Halfvarson","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib12","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.3748\/wjg.v12.i23.3668","article-title":"Family and twin studies in inflammatory bowel disease","volume":"12","author":"Halme","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2014.04.005_bib13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/003655200451207","article-title":"Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study","volume":"35","author":"Orholm","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.bpg.2014.04.005_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bpg.2014.04.005_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrg3502","article-title":"Genetic insights into common pathways and complex relationships among immune-mediated diseases","volume":"14","author":"Parkes","year":"2013","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.bpg.2014.04.005_bib16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/gut.32.8.913","article-title":"Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease","volume":"32","author":"Murch","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stool as a marker of intestinal inflammation","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2014.04.005_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0016-5085(92)90100-D","article-title":"Enhanced mucosal cytokine production in inflammatory bowel disease","volume":"102","author":"Pullman","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1074-7613(00)80038-2","article-title":"Impaired on\/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies","volume":"10","author":"Kontoyiannis","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.bpg.2014.04.005_bib20","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib21","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2009.02.001","article-title":"Biological therapies for inflammatory bowel diseases","volume":"136","author":"Rutgeerts","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib22","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","article-title":"Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists","volume":"151","author":"Mohler","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib24","doi-asserted-by":"crossref","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha","volume":"2","author":"Shealy","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.bpg.2014.04.005_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib26","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2014.04.005_bib28","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib29","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib30","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/MIB.0b013e318281333b","article-title":"Mechanisms of action of anti-tumor necrosis factor alpha agents in Crohn's disease","volume":"19","author":"Peake","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2014.04.005_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2010.10.008","article-title":"Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner","volume":"140","author":"Vos","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib32","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib33","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway","volume":"121","author":"Lugering","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib34","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm1110-1194","article-title":"Inside the microbial and immune labyrinth: totally gutted","volume":"16","author":"Macdonald","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib35","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.3462","article-title":"In\u00a0vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease","volume":"20","author":"Atreya","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/jir.1994.14.235","article-title":"Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells","volume":"14","author":"Fais","year":"1994","journal-title":"J\u00a0Interferon Res"},{"key":"10.1016\/j.bpg.2014.04.005_bib37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.4049\/jimmunol.157.3.1261","article-title":"Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5","volume":"157","author":"Fuss","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib38","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/j.gastro.2011.02.016","article-title":"Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases","volume":"140","author":"Strober","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib39","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gut.2005.079434","article-title":"A\u00a0dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease","volume":"55","author":"Reinisch","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib40","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/gut.2005.079392","article-title":"Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease","volume":"55","author":"Hommes","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ibd.21038","article-title":"Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study","volume":"16","author":"Reinisch","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2014.04.005_bib42","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A\u00a0randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib44","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib45","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib46","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib47","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0016-5085(97)70128-8","article-title":"Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells","volume":"112","author":"Monteleone","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib48","first-page":"823","article-title":"Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease","volume":"150","author":"Parronchi","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bpg.2014.04.005_bib49","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20061099","article-title":"Interleukin-23 drives innate and T cell-mediated intestinal inflammation","volume":"203","author":"Hue","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.immuni.2006.05.017","article-title":"Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology","volume":"25","author":"Uhlig","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.bpg.2014.04.005_bib51","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A\u00a052-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib53","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","article-title":"Paradoxical inflammation induced by anti-TNF agents in patients with IBD","volume":"9","author":"Cleynen","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2014.04.005_bib54","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib55","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2014.04.005_bib56","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ng.717","article-title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci","volume":"42","author":"Franke","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.bpg.2014.04.005_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00439-007-0397-0","article-title":"Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis","volume":"122","author":"Capon","year":"2007","journal-title":"Hum Genet"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2014.04.005_bib58","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/mi.2008.45","article-title":"IL-12 family members in experimental colitis","volume":"1","author":"Neurath","year":"2008","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib59","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0952-7915(99)00032-1","article-title":"Animal models of mucosal inflammation and their relation to human inflammatory bowel disease","volume":"11","author":"Blumberg","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib60","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib62","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/ibd.20475","article-title":"IL-23\/IL-17 immunity as a hallmark of Crohn's disease","volume":"14","author":"Holtta","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2014.04.005_bib63","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib64","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib65","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease","volume":"142","author":"Targan","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib66","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib67","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/gutjnl-2012-302525","article-title":"Seventeen in Crohn's disease: less prime than we thought?","volume":"61","author":"Raine","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib68","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2012-304154","article-title":"Secukinumab failure in Crohn's disease: the yeast connection?","volume":"62","author":"Colombel","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2014.04.005_bib70","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000268129","article-title":"Yeasts: neglected pathogens","volume":"27","author":"Poulain","year":"2009","journal-title":"Dig Dis"},{"key":"10.1016\/j.bpg.2014.04.005_bib71","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2006.02.009","article-title":"Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease","volume":"130","author":"Standaert-Vitse","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib72","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/ibd.20228","article-title":"Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans","volume":"13","author":"Schaffer","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2014.04.005_bib73","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/ajg.2009.225","article-title":"Candida albicans colonization and ASCA in familial Crohn's disease","volume":"104","author":"Standaert-Vitse","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2014.04.005_bib74","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1126\/science.1221789","article-title":"Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis","volume":"336","author":"Iliev","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.bpg.2014.04.005_bib75","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bpg.2014.04.005_bib76","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib77","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clim.2003.09.013","article-title":"Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice","volume":"110","author":"Ogawa","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib78","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A\u00a0protective function for interleukin 17A in T cell-mediated intestinal inflammation","volume":"10","author":"O'Connor","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib79","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.20071978","article-title":"Regulation of inflammatory responses by IL-17F","volume":"205","author":"Yang","year":"2008","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib80","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/01.MIB.0000218764.06959.91","article-title":"Critical role of IL-17 receptor signaling in acute TNBS-induced colitis","volume":"12","author":"Zhang","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2014.04.005_bib81","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.bpg.2014.04.005_bib82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.gastro.2012.05.015","article-title":"Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease","volume":"143","author":"Mayer","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib83","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib84","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bpg.2014.04.005_bib85","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn's disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib86","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T\u00a0cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib87","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/cimm.1996.0195","article-title":"Costimulation of the CD3 pathway by CD28 ligation in human intestinal lymphocytes","volume":"171","author":"Ebert","year":"1996","journal-title":"Cell Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib88","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00054725-200201000-00005","article-title":"Interleukin-2-deficient mice develop colitis in the absence of CD28 costimulation","volume":"8","author":"Boone","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2014.04.005_bib89","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.20091618","article-title":"OX40 is required for regulatory T cell-mediated control of colitis","volume":"207","author":"Griseri","year":"2010","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib90","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2014.04.005_bib91","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev.immunol.021908.132657","article-title":"Regulatory lymphocytes and intestinal inflammation","volume":"27","author":"Izcue","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bpg.2014.04.005_bib92","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.bpg.2014.04.005_bib93","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.06.009","article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease","volume":"145","author":"Panes","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib94","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.04.048","article-title":"Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial","volume":"145","author":"Cosnes","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2014.04.005_bib95","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib96","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/gutjnl-2011-300904","article-title":"New therapies for inflammatory bowel disease: from the bench to the bedside","volume":"61","author":"Danese","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib97","doi-asserted-by":"crossref","first-page":"e1000534","DOI":"10.1371\/journal.pgen.1000534","article-title":"Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions","volume":"5","author":"Raychaudhuri","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.bpg.2014.04.005_bib98","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bpg.2014.04.005_bib99","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ng1954","article-title":"A\u00a0genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1","volume":"39","author":"Hampe","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.bpg.2014.04.005_bib100","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nature13044","article-title":"A\u00a0Crohn's disease variant in Atg16l1 enhances its degradation by caspase 3","volume":"506","author":"Murthy","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bpg.2014.04.005_bib101","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature12599","article-title":"Paneth cells as a site of origin for intestinal inflammation","volume":"503","author":"Adolph","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bpg.2014.04.005_bib102","article-title":"Genomic ATG16L1 risk allele-restricted Paneth cell ER stress in quiescent Crohn's disease","author":"Deuring","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib103","article-title":"ATG16L1 Crohn's disease risk stresses the endoplasmic reticulum of Paneth cells","author":"Kaser","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2014.04.005_bib104","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nature13060","article-title":"Cell biology: stressful genetics in Crohn's disease","volume":"506","author":"Kaser","year":"2014","journal-title":"Nature"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691814000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691814000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T16:46:32Z","timestamp":1689180392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691814000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1521691814000493"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2014.04.005","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Not all monoclonals are created equal \u2013 Lessons from failed drug trials in Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2014.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}